Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.
The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.
A new imaging study found that patients who develop joint pain after cancer immunotherapy often show significant inflammation and joint damage on MRI—even when physical signs of arthritis are absent.
A large-scale analysis of physical therapies for knee osteoarthritis found knee bracing, hydrotherapy, and exercise to be the most effective options for reducing pain and improving function.
The addition of methotrexate to adalimumab for the treatment of plaque psoriasis may not improve drug survival, efficacy, or safety compared with adalimumab alone, according to a large real-world cohort study.
At EULAR 2025, researchers presented data showing aconitine reduced bone erosion and increased regulatory T cells in a rheumatoid arthritis mouse model.
New 2024 EULAR recommendations offer evidence-based guidance for the use of antirheumatic drugs during pregnancy, lactation, and conception planning in patients with rheumatic and musculoskeletal diseases.